Home > Akihiro Ohashi, Ph.D.
Akihiro Ohashi, Ph.D.
Deeply understanding “Cancer Hallmarks and Vulnerability” is important to develop the novel molecular target therapeutics. Genomic instability, which is one of the cancer hallmarks, is involved in various oncogenic cellular stresses, such as replication stress, mitotic stress, metabolic stress, and proteotoxic stress. Our research interests are how genomic instability would functionally interact with these oncogenic stresses, and these stress mediated by chromosome instability would contribute to cancer vulnerability against drug treatments. We are committed to apply our research findings for development of the innovative cancer therapeutics in collaboration with a number of academia, biotech companies, and pharmaceuticals.
- Genomic instability
- DNA replication and repair
- Cancer drug discovery
- Molecular target therapy
- Chromosome missegregation
- DNA replication stress
- Molecular target therapy
- Drug discovery
- BiomarkerTranslational research
- Mechanistic analysis for drug candidates targeting DNA replication stress
- Aneuploid-/polyploidy-mediated stress response and target discovery for chromosome instability
- Screening of synthetic lethal genes for DNA repair inhibitors
Open projects for collaboration
- Molecular target discovery for cancer therapeutics in genomic instability
- Drug discovery and translational research in DNA replication stress
- Biomarker seeing for the molecular target therapy
1993-1997 Dep. Agriculture, Agriculture Engineering, Kyoto University (B.S.)
1997-1999 Dep. Agriculture, Reproductive Biology, Kyoto University (M.S.)
1999-2002 Dep. Agriculture, Reproductive Biology, Kyoto University (Ph.D.)
2002-2004 Postdoctoral Fellow, Radiation Oncology, Mayo Clinic (Dr. Junjie Chen)
2004-2006 Postdoctoral Fellow, Laboratory Medicine and Pathology, Mayo Clinic (Dr. Fergus Couch)
2006-2007 Research Scientist, Oncology Drug Discovery Unit, Takeda Pharmaceutical Company, Ltd.
2007-2016 Senior Research Scientist, Oncology Drug Discovery Unit, Takeda Pharmaceutical Company, Ltd.
2016-2017 Group Head, Oncology Drug Discovery Unit, Takeda Pharmaceutical Company, Ltd.
2017-2018 Senior Scientist, Oncology Drug Discovery Unit, Takeda Pharmaceuticals International, Inc.
2018-present Division Head, Translational Genomics, Exploratory Oncology Research & Clinical Trial Center, National Cancer Center
- Ohashi A.*, Ohori M., and Iwai K.*corresponding author Motor activity of centromere-associated protein-E is required for its localization at the center of the midbody to regulate cytokinetic abscissionOncotarget 7 (48): 79964-79980. 2016. DOI: 10.18632/oncotarget.13206
- Ohashi A.*, Ohori M., Iwai K., Nambu T., Miyamoto M., Kawamoto T. and Okaniwa M.*corresponding author A Novel Time-Dependent CENP-E Inhibitor with Potent Antitumor Activity PLOS ONE 10 (12): e0144675. 2015. DOI: 10.1371/journal.pone.0144675
- Ohashi A.*, Ohori M., Iwai K., Nakayama Y., Nambu T., Morishita D., Kawamoto T., Miyamoto M., Hirayama T., Okaniwa M., Banno H., Ishikawa T., Kandori H. and Iwata K.*corresponding author Aneuploidy generates proteotoxic stress and DNA damage concurrently with p53-mediated post-mitotic apoptosis in SAC-impaired cells. Nat Commun. 6:7668. DOI: 10.1038/ncomms8668. 2015
- Mondal M., Ohashi A., Yang L., Rowley M. and Couch FJ.Tex14, a Plk1 regulated protein, is required for kinetochore-microtubule attachment and regulation of the spindle assembly checkpoint.Mol Cell. 45(5):680-695. 2012
- Rowley M., Ohashi A., Mondal G., Mills L., Yang L., Zhang L., Muders M., Smyrk T. and Couch FJ.Inactivation of Brca2 promotes Trp53-associated but inhibits KrasG12D-dependent pancreatic cancer development in mice.Gastroenterology 140(4):1303-1313. 2011
- Xia B., Sheng Q., Nakanishi K., Ohashi A., Wu J., Christ N., Liu X., Jasin M., Couch FJ., Livingston DM.Control of BRCA2 cellular and clinical functions by a nuclear partner, PALB2.Mol Cell. 22(6):719-29 2006
- Ohashi A., Zdzienicka M., Chen J. and Couch FJ.Fanconi anemia complementation group D2 (FANCD2) functions independently of BRCA2- and RAD51-associated homologous recombination in response to DNA damage.J Biol Chem. 280(15):14877-83. 2005
- Wu K., Hinson SR., Ohashi A., Farrugia D., Wendt P., Tavtigian SV., Deffenbaugh A., Goldgar D., Couch FJ.Functional evaluation and cancer risk assessment of BRCA2 unclassified variants.Cancer Res. 65(2):417-26. 2005